Nicox Appoints Robert N. Weinreb, M.D. and Sanjay G. Asrani, M.D. to its Glaucoma Clinical Advisory Board

Sophia Antipolis Cédex, FRANCE

Press Release
Nicox Appoints Robert N. Weinreb, M.D. and Sanjay G. Asrani, M.D. to its Glaucoma Clinical Advisory Board

July 13, 2021 – release at 7:30 am CET
Sophia Antipolis, France

Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that two internationally recognized experts in glaucoma, Robert N. Weinreb, M.D., Distinguished Professor and Chair, Ophthalmology and Director, Shiley Eye Institute, University of California San Diego, and Sanjay G. Asrani, M.D., Professor of Ophthalmology, Duke University, will be joining the Nicox Glaucoma Clinical Advisory Board. The Advisory Board is composed of key clinical investigators and opinion leaders in the field who support and guide the development of our innovative nitric oxide (NO)-donating compounds as potential intraocular pressure (IOP)-lowering medications.

Dr. José Boyer, Interim Head of R&D at Nicox, said We are pleased to welcome two highly respected new members to the Nicox Glaucoma Clinical Advisory Board as we advance towards the pivotal Phase 3 results from the first NCX 470 clinical trial in glaucoma and continue to build out our research platform of innovative nitric oxide-donating medications. Both Dr. Weinreb and Dr. Asrani bring vast clinical and research expertise in glaucoma, which will complement and strengthen the existing board composition. We look forward to working closely with them.

Nitric oxide has already been demonstrated to have a role in the control of intraocular pressure, and Nicox is at the forefront of the development of new drugs in this area. NCX 470 is a very promising product candidate in advanced development and I look forward to working with the Nicox team in bringing it to glaucoma patients,said Dr. Weinreb.

Dr. Asrani said This is an exciting time to be joining the Nicox Clinical Advisory Board. NCX 470 has demonstrated very promising efficacy in the Phase 2 Dolomites trial. The design of the pivotal Phase 3 trials head-to-head against the prostaglandin analog latanoprost offer an opportunity of generating data for a new molecule in glaucoma directly against one of the most prescribed treatments.  

Robert N. Weinreb, M.D. is the Distinguished Professor and Chair of Ophthalmology at the University of California San Diego. He also is the Director of both the Shiley Eye Institute and the Hamilton Glaucoma Center, holder of the Morris Gleich, MD Chair in Glaucoma, and Distinguished Professor of Bioengineering. He received his medical degree from Harvard Medical School. Patients from throughout the world seek his medical and surgical care.

Dr. Weinreb is the recipient of numerous prestigious awards and prizes, his research has been cited more than 70,000 times, and his h-impact factor is 132 (July 2021).

Dr. Weinreb has trained more than 170 post-doctoral fellows, 22 department Chairs throughout the world, and many others who hold distinguished positions in academia and industry. He is a past President of the Association for Research in Vision and Ophthalmology (ARVO), American Glaucoma Society (AGS), World Glaucoma Association (WGA), American Glaucoma Society Foundation (AGSF), and the Latin Glaucoma Society (PAGS). With Roger Hitchings (London) and Erik Greve (Amsterdam), he founded the World Glaucoma Association.

Sanjay Asrani M.D. is Professor of Ophthalmology at Duke University in Durham, North Carolina, U.S., and Director of the Duke Eye Center of Cary and the Duke Glaucoma OCT Reading Center. Dr. Asrani is the recipient of numerous awards, including the Career Development Award from Research to Prevent Blindness, the Helen Keller Scientist Award from the American Glaucoma Society, the Senior Achievement and the Secretariat Awards from the American Academy of Ophthalmology. Dr. Asrani has over 90 peer reviewed publications and serves on the editorial board of Journal of Glaucoma, Advances in Therapy, and Ophthalmology and Therapeutics. He has developed a new glaucoma implant and a new software for OCT for glaucoma diagnosis.

The other members of the Nicox Glaucoma Clinical Advisory Board are Dr. Robert D. Fechtner, MD (Chairman), Dr. Donald L. Budenz, MD MPH, Dr. Steven Mansberger, MD MPH and Dr. Tom R. Walters, MD.
About Nicox
Nicox S.A. is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox’s lead program in clinical development is NCX 470, a novel nitric oxide-donating prostaglandin analog, for lowering intraocular pressure in patients with glaucoma. The company is also developing NCX 4251, a proprietary formulation of fluticasone, for acute exacerbations of blepharitis. Nicox generates revenue from VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, and ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Eyevance Pharmaceuticals, LLC, in the U.S. and Ocumension Therapeutics in the Chinese and in the majority of South East Asian markets.

Nicox is headquartered in Sophia Antipolis, France, is listed on Euronext Paris (Compartment B: Mid Caps; Ticker symbol: COX) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes.

For more information on Nicox, its products or pipeline, please visit:
Analyst coverage

Bryan, Garnier & Co         Victor Floc’h        Paris, France
Cantor Fitzgerald        Louise Chen        New York, U.S.
Edison Investment Research        Pooya Hemami        London, UK
H.C. Wainwright & Co        Yi Chen        New York, U.S.
Kepler Cheuvreux        Damien Choplain        Paris, France
The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports.
Gavin Spencer
Executive Vice President, Chief Business Officer
& Head of Corporate Development
T +33 (0)4 97 24 53 00
Investors & Media
United States & Europe
LifeSci Advisors, LLC
Sandya von der Weid
T +41 78 680 05 38
LifeSci Advisors, LLC
Sophie Baumont
M +33 (0)6 27 74 74 49
Forward-Looking Statements
The information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.

Risks factors which are likely to have a material effect on Nicox’s business are presented in the 3rd chapter of the ‘Document d’enregistrement universel, rapport financier annuel et rapport de gestion 2020’ filed with the French Autorité des Marchés Financiers (AMF) on March 1, 2021 which are available on Nicox’s website (
Nicox S.A.
Drakkar 2
Bât D, 2405 route des Dolines
CS 10313, Sophia Antipolis
06560 Valbonne, France
T +33 (0)4 97 24 53 00
F +33 (0)4 97 24 53 99